How to Get Retatrutide in 2026

Retatrutide is not FDA-approved and is not sold at retail pharmacies. As of May 2026, the FDA has not received a New Drug Application from Eli Lilly, and the agency has stated plainly that retatrutide cannot be used in compounding under federal law. That removes two access paths most people assume exist.

Two realistic paths remain. The first is enrolling in one of Eli Lilly's TRIUMPH Phase 3 trials, which offers pharmaceutical-grade retatrutide for free with medical oversight (with placebo risk). The second is buying from a research-use peptide supplier with verifiable third-party testing. PepPal's two named picks are Peptide Partners and Orbitrex Peptides, both of which carry Finnrick testing data buyers can review independently.

Retatrutide (development code LY3437943) is an investigational triple-agonist peptide from Eli Lilly. It activates three hormone receptors at once: GLP-1, GIP, and glucagon. Researchers sometimes call it a triple-G molecule or shorthand it as GLP-3. Eli Lilly is also the company behind tirzepatide (Zepbound and Mounjaro).

The triple-receptor mechanism is the core reason retatrutide outperformed dual and single agonists in clinical trials. Semaglutide hits one receptor. Tirzepatide hits two. Retatrutide hits three. That difference shows up in the weight-loss numbers below.

No. As of May 18, 2026, retatrutide is not approved by the FDA. It is also not approved by the EMA, MHRA, TGA, or Health Canada. Eli Lilly has not yet submitted a New Drug Application. Phase 3 readouts have happened (TRIUMPH-4 on December 11, 2025, and TRANSCEND-T2D-1 on March 19, 2026), but more TRIUMPH trials still need to report before an NDA goes in.

A lot of competitor guides list compounding pharmacies as a third access path. That framing is out of date. The FDA stated directly on its own GLP-1 concerns page that retatrutide and cagrilintide cannot be used in compounding under federal law. The agency has also issued warning letters to companies selling compounded retatrutide.

Retatrutide fails all three eligibility paths for 503A and 503B compounding:

Semaglutide and tirzepatide had a narrow shortage-related window where compounding was temporarily permitted. That window never opened for retatrutide because there is no FDA-approved retatrutide product to be in shortage in the first place. Any pharmacy currently selling "compounded retatrutide" is operating outside the 503A and 503B framework. The FDA sent more than 50 warning letters to GLP-1 compounders in September 2025, and several letters named retatrutide specifically.

Eli Lilly is running the TRIUMPH Phase 3 program through 2026. Enrolling gets you pharmaceutical-grade retatrutide for free, with medical supervision and structured monitoring. The trade-off is placebo risk (typically about one in three participants), strict eligibility criteria, and a multi-month commitment.

Research-use suppliers sell retatrutide as a lyophilized powder labeled "for research-use only, not for human consumption." This is the route most non-trial buyers actually use. The quality range is wide, so this is where supplier verification matters the most. PepPal's two named picks are Peptide Partners and Orbitrex Peptides, both with public Finnrick testing data.

Both suppliers carry retatrutide and both have independent Finnrick testing history buyers can review. Peptide Partners is PepPal's top pick because Finnrick's current rating is A (Great) across a larger sample volume. Orbitrex is the practical backup option, with a Finnrick B (Good) rating across a slightly smaller sample volume. Both are real options; the choice depends on testing depth and what feels right after reviewing supplier policies.

Both PepPal picks publish testing data, but verification is still on the buyer. Run this checklist on any retatrutide vial before you order, including from PepPal's named picks.

Retatrutide's reputation is built on two main readouts: Phase 2 in 2023 and TRIUMPH-4 Phase 3 in December 2025. Both are published, peer-reviewed, or reported through formal trial channels.

Reported side effects from clinical trials fall into two buckets. The first is the standard GLP-1 family profile: nausea, vomiting, diarrhea, and constipation, mostly mild to moderate, mostly during dose escalation. The second is something specific to higher retatrutide doses: dysesthesia, which can present as tingling, skin sensitivity, or tenderness to the touch. The December 2025 TRIUMPH-4 readout flagged this signal at the 12 mg dose.

Real 2026 retatrutide pricing depends entirely on which path you take. Clinical trial enrollment is free. Compounded retatrutide is not a legitimate option under federal law and should not be price-shopped. Research-use suppliers price by vial size and per-mg cost. Branded pricing does not exist yet because the drug is not approved.

When branded retatrutide launches, it will likely follow the same launch-pricing pattern as Zepbound. That suggests roughly $1,000+ per month before any savings card or insurance offset. That is the realistic future cost baseline for FDA-approved retatrutide.

This page is current as of May 18, 2026. Several things will change soon and should be re-confirmed before you act on them.